Fast, fully automated analysis of voriconazole from serum by LC–LC–ESI-MS–MS with parallel column-switching technique

Egle, Hannes; Trittler, Rainer; König, Armin; Kümmerer, Klaus

doi:10.1016/j.jchromb.2004.10.069

Cited by 52 publications

(38 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also used linezolid as IS, an antibiotic which may be co-administered in clinical practice, while the use of flavone, as we set in our methodology, makes our method more applicable to the analysis of immunocompromized patients. More recently LC-MS/MS methods have been developed to the purpose of antifungal TDM [25][26][27][28][29][30][31][32], but MS facilities are not always available in standard hospital laboratories. Our developed method, based on HPLC-UV system, reveals a good performance to this aim.…”

Section: Resultsmentioning

confidence: 99%

“…Several reported the use of high performance liquid chromatography coupled with ultraviolet determination (HPLC-UV) [4,[13][14][15][16][17][18][19][20][21][22][23][24]. More recently, liquid chromatographic methods based on mass spectrometry (LC-MS/MS) detection have been developed to this purpose [25][26][27][28][29][30][31][32], although MS facilities are not always available in standard hospital laboratories, because they are expensive compared with a simple HPLC system. reached from patients and approval for the research was obtained from local ethics committee.…”

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

A New HPLC Validated Method for Therapeutic Monitoring Of Triazoles in Human Plasma: First Results in Leukaemic Patients

Francia

Cardalana²,

P³

et al. 2015

Clin Exp Pharmacol

View full text Add to dashboard Cite

Therapeutic drug monitoring of triazoles is widely used in clinical practice to optimize therapy, especially in those patients who need antifungal treatment as co-medications. Here it is described development and validation of a new chromatographic method in order to quantify voriconazole and posaconazole in human plasma by ultraviolet detection.After liquid extraction of analytes from plasma using acetonitrile, samples are evaporated to dryness and then reconstituted in mobile phase for chromatographic separation. Analysis is achieved on C18 reverse phase column and eluate is monitored at 250 nm. Mobile phase consisted of 35% water, 15% methanol, 50% acetonitrile. Flavone was used as internal standard; retention times (minutes) were, respectively, for voriconazole 3.9, posaconazole 7.9, flavone 7.1.Accuracy and variability were assayed by inter-and intra-day validation, conducted on three separate days. Methodology was used for the analysis of plasma samples of acute myeloid leukaemia patients in therapy with voriconazole or posaconazole for treatment of fungal infections, in order to perform therapeutic monitoring of antifungal drugs levels.Mean inter-and intra-day accuracy and variability were acceptable for both compounds; thus, method developed resulted linear in the range 0.125-8 µg/mL. Limits of quantification and limits of detection for voriconazole and posaconazole are, respectively, 0.100 and 0.050 µg/mL, and 0.030 and 0.020 µg/mL.It has been observed that voriconazole and posaconazole circulating levels achieved in patients are on average below the therapeutic range defined in literature.In conclusion, method developed and validated in order to quantify voriconazole and posaconazole in human plasma is accurate and precise; it is easily applicable and reproducible, and, therefore, it could be an useful tool in clinical routine to better manage patients in case of multi-therapy approach.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Patientsmentioning

confidence: 99%

A New HPLC Validated Method for Therapeutic Monitoring Of Triazoles in Human Plasma: First Results in Leukaemic Patients

Francia

Cardalana²,

P³

et al. 2015

Clin Exp Pharmacol

View full text Add to dashboard Cite

show abstract

“…The quantification of voriconazole in biological fluids by HPLC [7][8][9][10][11][12] and by LC-MS [13][14][15][16][17][18][19][20] methods has been reported. Because voriconazole determination to monitor therapeutic regiments is not yet established, often only a few samples have to be measured in a single run.…”

Section: Abstract: Voriconazole; Liquid Chromatography Coupled With mentioning

confidence: 99%

“…On the other hand, clinicians often require results on the same day, which makes the turnaround time for drug analysis critical, especially if other drugs have to be measured with the same equipment. Recently, several different methods have been described using LC-MS or LC-MS/MS techniques for the determination of voriconazole in the aqueous humor, 13) serum, 14,15) and plasma, 16,17) or simultaneously quantitate concentrations of different antifungal drugs including voriconazole in human plasma 18,19) or serum. 20) However, the analysis times were found be 4 to 13 min for these methods.…”

Section: Abstract: Voriconazole; Liquid Chromatography Coupled With mentioning

confidence: 99%

Fast and Reliable Determination of Voriconazole in Human Plasma by LC-APCI-MS/MS

Xiong

Duan

Zhai

et al. 2010

Bioscience, Biotechnology, and Biochemistry

View full text Add to dashboard Cite

“…[55][56][57][58][59][60][61][62][63][64][65][66][67][68] Most of these assays use high-performance liquid chromatography (HPLC) methods either with ultraviolet (UV) detection or coupled with mass spectrophotometry. [56][57][58][59][60][61][62][63][64][65][66][67][68] Other methods such as microbiological assays have also been investigated. 55,56 Some of the HPLC methods developed for quantifying voriconazole in plasma are limited by long turn-around time, complex procedures, and/or narrow quantification range that does not adequately reflect concentrations of voriconazole in the clinical setting.…”

Section: Drug Assaymentioning

confidence: 99%

Role of Therapeutic Drug Monitoring of Voriconazole in the Treatment of Invasive Fungal Infections

Kuo

Ensom

2009

CJHP

View full text Add to dashboard Cite

Background: Voriconazole is a broad-spectrum, second-generation triazole antifungal agent with demonstrated efficacy in the treatment of invasive fungal infections caused by Aspergillus spp. and Candida spp. Given the characteristically poor prognosis of patients with invasive fungal infections and the protracted duration of treatment required, therapeutic monitoring of voriconazole is, in theory, an attractive method to optimize antifungal therapy. Objective:To determine the utility of therapeutic drug monitoring for voriconazole. Methods:A previously published decision-making algorithm was used to assess the currently available literature on therapeutic drug monitoring of voriconazole.Results: Several analytical methods can be used to quantify plasma or serum concentrations of voriconazole. Reasons for therapeutic monitoring of this drug include wide variability both within and between individuals secondary to drug properties, drug-drug interactions, and disease states. Furthermore, voriconazole follows nonlinear pharmacokinetics with saturable hepatic clearance. Another potential factor in favour of therapeutic drug monitoring for voriconazole is genetic polymorphism of CYP2C19, whereby patients who are homozygous for poor metabolism (about 19% of non-Indian Asians) can have 4-fold greater exposure to voriconazole. The concentrations of this drug are also greater in patients with hepatic impairment. Drug-drug interactions with other substrates of CYP2C9, CYP2C19, and CYP3A4 can also alter voriconazole concentrations. However, the correlations between plasma concentrations of voriconazole and its efficacy and toxicity are not well defined. Although lower and upper target thresholds of 0.25-2 mg/L and 4-6 mg/L, respectively, have been suggested, studies to date have not been appropriately designed or powered to reveal any definitive association. Conclusions:Routine therapeutic drug monitoring of voriconazole is not recommended except in certain circumstances, such as lack of response to therapy or evidence of toxicity, in which case selective monitoring of voriconazole concentrations may be of clinical utility. Méthodes : Un algorithme de prise de décision publié a été utilisé pour évaluer la documentation actuellement disponible sur le suivi thérapeutique pharmacologique du voriconazole. Résultats :Plusieurs méthodes analytiques peuvent servir à quantifier les concentrations sériques ou plasmatiques de voriconazole. Les raisons de recourir au suivi thérapeutique pharmacologique de ce médicament sont notamment la grande variabilité intra et interindividuelle attribuable aux propriétés du médicament, aux interactions médicament-médicament et aux affections. De plus, le voriconazole a un comportement pharmacocinétique non linéaire en raison d'une clairance hépatique saturable. Un autre facteur potentiellement en faveur du suivi thérapeutique pharmacologique du voriconazole est le polymorphisme génétique du CYP2C19 qui, chez les patients homozygotes ayant un faible métabolisme (environ 19 % des Asiatiques ...

show abstract

Fast, fully automated analysis of voriconazole from serum by LC–LC–ESI-MS–MS with parallel column-switching technique

Cited by 52 publications

References 33 publications

A New HPLC Validated Method for Therapeutic Monitoring Of Triazoles in Human Plasma: First Results in Leukaemic Patients

A New HPLC Validated Method for Therapeutic Monitoring Of Triazoles in Human Plasma: First Results in Leukaemic Patients

Fast and Reliable Determination of Voriconazole in Human Plasma by LC-APCI-MS/MS

Role of Therapeutic Drug Monitoring of Voriconazole in the Treatment of Invasive Fungal Infections

Contact Info

Product

Resources

About